About 40 percent of head and neck cancer survivors do not return to work
the ONA take:
According to a study published in the journal Head & Neck, researchers from Jena University Hospitial and University Medical Centre in Germany have found that many survivors of head and neck cancer do not return to work.
For the exploratory study, researchers identified 55 head and neck cancer survivors no older than 60 years of age.
All participants completed a survey that included subscales from various health questionnaires. Results showed that the rate of employed patients decreased from 75% of patients prior to diagnosis to 33% at an average of 66.8 months following diagnosis.
Researchers found that current employment was associated with more difficult physical work prior to diagnosis, surgical treatment, and current risky consumption of alcohol.
The study also showed that unemployed survivors reported decreased functional and social well-being scores and increased depression scores.
The findings suggest that psychosocial variables were significantly associated to employment, but the authors note that further research is necessary to evaluate these relationships.
Many survivors of head and neck cancer do not return to work.
Sign Up for Free e-newsletters
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- 5-Year Overall Survival in Endometrial Cancer Not Improved With Chemoradiotherapy
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Follow-Up After Treatment Lacking for Younger Cancer Survivors
- Adjuvant Vemurafenib Does Not Improve Disease-Free Survival in Melanoma
- Profile of Buparlisib and its Potential in the Treatment of Breast Cancer: Evidence to Date
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|